Search results
Showing 8001 to 8050 of 8150 results
Endometriosis: diagnosis and management - diagnosing endometriosis
In development [GID-NG10392] Expected publication date: 10 July 2024
In development [GID-NG10398] Expected publication date: TBC
Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome
In development [GID-DG10074] Expected publication date: 11 September 2024
Awaiting development [GID-TA10814] Expected publication date: TBC
Awaiting development [GID-TA11330] Expected publication date: TBC
Status ...
Status ...
The panel agreed the technology is not appropriate to be selected for guidance development as there is insufficient evidence. ...
We are listening to your views on this Diagnostics guidance. Comments close 4 June 2024.
Awaiting development [GID-TA11535] Expected publication date: TBC
In development [GID-TA10813] Expected publication date: TBC
In development [GID-TA11390] Expected publication date: 24 July 2024
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235
In development [GID-TA11246] Expected publication date: TBC
Mirikizumab for treating moderately to severely active Crohn's disease ID6244
In development [GID-TA11267] Expected publication date: TBC
We are listening to your views on this Diagnostics guidance. Comments close 5 June 2024.
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development [GID-TA11086] Expected publication date: TBC
In development [GID-NG10210] Expected publication date: 16 July 2024
All NICE products on older people. Includes any guidance, advice and quality standards.
In development [GID-TA10615] Expected publication date: TBC
In development [GID-HTE10030] Expected publication date: 15 August 2024
Awaiting development [GID-TA11544] Expected publication date: TBC
In development [GID-TA11397] Expected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
In development [GID-TA11253] Expected publication date: TBC
Awaiting development [GID-TA11093] Expected publication date: TBC
Awaiting development [GID-TA11424] Expected publication date: TBC
In development [GID-TA11545] Expected publication date: 10 September 2025
In development [GID-TA11455] Expected publication date: TBC
Adalimumab for treating early Dupuytren's contracture TS ID 11870
Awaiting development [GID-TA11363] Expected publication date: TBC
In development [GID-TA10655] Expected publication date: 11 September 2024
In development [GID-TA11546] Expected publication date: 10 September 2025
Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica
Discontinued [GID-IP2806]
Discontinued [GID-IP1043]
Optical Coherence Tomography to guide percutaneous coronary intervention
In development [GID-IPG10394] Expected publication date: TBC
In development [GID-TA11461] Expected publication date: TBC
In development [GID-TA11523] Expected publication date: TBC
In development [GID-NG10336] Expected publication date: 19 June 2025
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
In development [GID-TA11106] Expected publication date: TBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]
In development [GID-TA11132] Expected publication date: 26 June 2024
We are listening to your views on this Technology appraisal guidance. Comments close 10 June 2024.
Awaiting development [GID-TA11248] Expected publication date: TBC
In development [GID-TA10778] Expected publication date: 11 December 2024
Awaiting development [GID-TA11346] Expected publication date: TBC
Awaiting development [GID-TA11511] Expected publication date: TBC
In development [GID-TA11408] Expected publication date: TBC